

Application No. 10/755,038
In Reply to Notice of April 7, 2008
Paper Dated: May 7, 2008
Attorney Docket No. 2111-040037

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**ON APPEAL FROM THE PRIMARY EXAMINER TO THE
BOARD OF PATENT APPEALS AND INTERFERENCES**

Application No. : 10/755,038 Confirmation No.: 7887
Appellant : Avram Reuben Gold
Filed : January 9, 2004
Title : METHOD OF TREATING FUNCTIONAL SOMATIC
SYNDROMES AND DIAGNOSING SLEEP DISORDERS
BASED ON FUNCTIONAL SOMATIC SYNDROME
SYMPTOMS
Group Art Unit : 3771
Examiner : Shumaya B. Ali
Customer No. : 28289

MAIL STOP APPEAL BRIEF – PATENTS
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

APPELLANT'S REVISED BRIEF UNDER 37 C.F.R. §41.37

Sir:

This Revised Brief is in response to the Notification of Non-Compliant Appeal Brief mailed April 7, 2008 and in further support of the Notice of Appeal filed electronically with the United States Patent and Trademark Office on November 7, 2007. No fee is believed to be due at this time for the filing of the Revised Brief as it is being submitted within the allowed thirty (30) day response time. The headings used hereinafter and that which is set forth under each heading are in accordance with 37 C.F.R. §41.37(c).


I hereby certify that this correspondence is being electronically submitted to the United States Patent and Trademark Office on May 7, 2008.	
 Signature	<u>Lisa R. McNary</u> (Name of Person Submitting Paper) <u>05/07/2008</u> Date

TABLE OF CONTENTS

I.	Real Party in Interest.....	3
II.	Related Appeals and Interferences.....	4
III.	Status of Claims.....	5
IV.	Status of Amendments.....	6
V.	Summary of Claimed Subject Matter.....	7
VI.	Grounds of Rejection to be Reviewed on Appeal.....	8
VII.	Argument.....	9
	Claims Appendix.....	22
	Evidence Appendix.....	25
	Related Proceedings Appendix.....	26

Application No. 10/755,038
In Reply to Notice of April 7, 2008
Paper Dated: May 7, 2008
Attorney Docket No. 2111-040037

I. REAL PARTY IN INTEREST

The Research Foundation of the State University of New York is the Assignee of the entire right, title, and interest to the above-identified application and, as such, is the real party in interest in this Appeal. An Assignment dated May 6, 2004 and recorded at Reel/Frame 015463/0510 on June 16, 2004 in the United States Patent and Trademark Office confirms the assignment to the Research Foundation of the State University of New York.

Application No. 10/755,038
In Reply to Notice of April 7, 2008
Paper Dated: May 7, 2008
Attorney Docket No. 2111-040037

II. RELATED APPEALS AND INTERFERENCES

There are no appeals or interferences known to the Appellant, the Appellant's undersigned legal representative, or the Assignee of the above-identified application which will directly affect or be directly affected by or have a bearing on the Board's decision in this Appeal.

III. STATUS OF CLAIMS

Claims 1, 5, 6, 8-12, 16, 17, 19, and 20 are pending and are appealed.

Claims 2-4, 7, 13-15, 18, and 21-28 have been cancelled.

Claims 1, 5, 6, 11, 12, 16, and 17 stand rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over the teachings of United States Patent No. 5,954,048 to Thornton ("Thornton"), which was misidentified in the August 7, 2007 Office Action as "Threnton US 6,769,910 B1."

Claims 8, 9, 19, and 20 stand rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over Thornton in view of United States Patent No. 6,752,766 to Kowallik et al. ("Kowallik").

Claim 10 stands rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over Thornton in view of United States Patent No. 5,378,686 to Bennett et al. ("Bennett").

Claims 1, 5, 6, 8-12, 16, 17, 19, and 20, which are the subject of this appeal, are reproduced in the Claims Appendix, which is attached hereto.

Application No. 10/755,038
In Reply to Notice of April 7, 2008
Paper Dated: May 7, 2008
Attorney Docket No. 2111-040037

IV. STATUS OF AMENDMENTS

All amendments to the claims in this application have been entered. The claims on appeal are the claims as amended by Appellant's Amendment in Anticipation of Appeal dated November 7, 2007. All of pending claims 1, 5, 6, 8-12, 16, 17, 19, and 20 were rejected for the fourth time in the August 7, 2007 Office Action.

V. SUMMARY OF CLAIMED SUBJECT MATTER

The independent claims involved in this appeal are claims 1 and 12. The following is a concise explanation of the subject matter set forth claims 1 and 12. Unless otherwise noted, all references to specific paragraph numbers throughout this Appeal Brief refer to the paragraph numbers in the original Specification filed on January 9, 2004.

A method of treating functional somatic syndromes is claimed in claim 1. The method includes the step of determining whether a patient suffers from inspiratory airflow limitation during sleep. (Specification, ¶ [0010], ¶¶ [0021]-[0022]). The method further includes the step of identifying the patient suffering from inspiratory airflow limitation during sleep as having a functional somatic syndrome. (Specification, ¶¶ [0009]-[0010], ¶¶ [0020]-[0024]). The functional somatic syndromes are described in the Appellant's Specification as physical syndromes without an organic disease explanation, demonstrable structural changes, or established biochemical abnormalities. (Specification, ¶ [0005]). Finally, the method includes the step of treating the patient with an upper airway stabilization technique. (Specification, ¶¶ [0024]-[0033]). The upper airway stabilization technique involves the stabilization of the airway with, for example, positive airway pressure therapy. (Specification, ¶¶ [0025]-[0028]).

A method of treating functional somatic syndromes is claimed in claim 12. The method includes the step of determining whether a patient suffers from inspiratory airflow limitation during sleep. (Specification, ¶ [0010], ¶¶ [0021]-[0022]). The method further includes the step of identifying this patient as having one or more symptoms of a functional somatic syndrome. (Specification, ¶ [0011], ¶ [0017], ¶¶ [0023]-[0024]). In addition, the method includes the step of treating the patient with an upper airway stabilization technique, the technique comprising stabilization of the airway with positive airway pressure therapy as one embodiment. (Specification, ¶¶ [0024]-[0033]).

There are no other independent claims involved in this Appeal, nor are there other dependent claims that are argued separately in this Appeal. Therefore, Appellant is not required to provide a concise explanation of any dependent claim pursuant to 37 C.F.R. § 41.37(c)(1)(v).

VI. GROUNDS OF REJECTION TO BE REVIEWED ON APPEAL

- A. Whether independent claim 1 was properly rejected under 35 U.S.C. § 103(a) over the teachings of Thornton?
- B. Whether independent claim 12 was properly rejected under 35 U.S.C. § 103(a) over the teachings of Thornton?

VII. ARGUMENT

A. Claim 1 Was Not Properly Rejected Since the Required *Prima Facie* Case of Obviousness Under 35 U.S.C. § 103(a) Over Thornton Has Not Been Established.

Claim 1 stands rejected under 35 U.S.C. § 103(a) as being obvious over Thornton alone. Appellant respectfully submits that the August 7, 2007 Office Action (“Office Action”) fails to establish a *prima facie* case of obviousness of claim 1 over Thornton and the rejection of this claim should be reversed.

When making a rejection under 35 U.S.C. § 103(a), the Examiner has the burden of establishing a *prima facie* case of obviousness. *In re Fritch*, 23 U.S.P.Q.2d 1780, 1783 (Fed. Cir. 1992). Establishing a *prima facie* case of obviousness first requires the Examiner to resolve the factual inquires set forth in the case of *Graham v. John Deere Co.*, 383 U.S. 1, 148 U.S.P.Q. 459 (1966). These inquires include: (1) determining the scope and content of the prior art, (2) ascertaining the differences between the claimed invention and the prior art, and (3) resolving the level of ordinary skill in the pertinent art. *Id.*, 383 U.S. at 17. Upon completing this analysis, the Examiner must then prove that, despite the differences between the prior art and the claimed invention, one skilled in the art would find it obvious to modify or combine the prior art in order to create the claimed invention. *KSR Int’l v. Teleflex, Inc.*, 82 U.S.P.Q.2d 1385, 1397 (S.Ct. 2007). This determination “must be based on consideration of the entire record, by a preponderance of evidence, with due consideration to the persuasiveness of any arguments and any secondary evidence.” *Manual of Patent Examining Procedure*, (Rev. 6, Sept. 2007) § 716.01(d); *In re Oetiker*, 24 U.S.P.Q.2d 1443, 1444 (Fed. Cir. 1992).

1. Scope and Content of the Prior Art

Thornton is directed to a device with an insertable oral section consisting of an upper arch and a lower arch. The arches are inserted into a user’s mouth so that the upper arch engages the user’s upper teeth and the lower arch engages the lower teeth. The upper arch and the lower arch are then connected by a hook and the hook forces the lower arch forward relative to the upper arch. The resulting forces cause the user’s lower jaw to be positioned forward or displaced relative to the upper jaw. Such positioning of the lower jaw causes the user’s breathing passageway to remain open and is known to treat certain sleep-related breathing

disorders like obstructive sleep apnea and, further, snoring. A continuous positive airway pressure (CPAP) system may also be associated with or connected to the device. Adjusting the air pressure from the CPAP system can act to increase the opening of the user's breathing passageway and may be used in cooperation with the lower jaw positioning feature to treat sleep related breathing disorders such as obstructive sleep apnea and, further, snoring.

2. Differences Between the Prior Art and the Claimed Invention

Claim 1 is directed to a method of treating functional somatic syndromes by: determining whether a patient suffers from inspiratory airflow limitation during sleep, identifying the patient as suffering from a functional somatic syndrome, and treating the patient with an upper airway stabilization technique. Appellant's claimed method is based on his pioneering recognition and discovery that inspiratory airflow limitation during sleep demonstrably plays a primary role in development of the functional somatic syndromes and, as a result, treatment of inspiratory airflow limitation via an upper airway stabilization technique, like positive airway pressure therapy as one provided example, "improves the symptoms/signs associated with the functional somatic syndromes." (Specification, ¶ [0066]). Accordingly, Appellant alone identifies a causal connection between inspiratory airflow limitation during sleep and the functional somatic syndromes and further teaches the corrective regimen of upper airway stabilization, whether by mechanical means and/or positive airway pressure therapy means, and the like.

As described by Appellant, functional somatic syndromes are defined as "physical syndromes without an organic disease explanation, demonstrable structural changes, or established biochemical abnormalities." (Specification, ¶ [0005]). A patient suffering from a functional somatic syndrome is usually characterized more by symptoms than by demonstrable and identifiable physical abnormalities. *Id.* Functional somatic syndromes, then, are a unique class of disorders for which current medical science has been unable to identify a unifying underlying cause. The foregoing definition of the functional somatic syndromes is corroborated by Dr. Mark Sanders, an expert in the field of Sleep Medicine, in his Declaration Under 37 C.F.R. § 1.132 ("Sanders Declaration") submitted on May 21, 2007. Dr. Sanders states that, "[Appellant's] disclosure correctly identifies a definition of functional somatic syndromes...that

comports with the medical literature relating to functional somatic syndromes.” (Sanders Declaration, ¶ 5).

It is readily apparent from a close inspection of Thornton that this reference fails to teach or suggest any possible causal connection or linkage between restricted or limited inspiratory airflow during sleep and the functional somatic syndromes which may be addressed via upper airway stabilization pursuant to Appellant’s disclosure. Only Appellant identifies the likely primary role of inspiratory airflow limitation during sleep and the functional somatic syndromes, (Specification, ¶ [0057]), and identifies corrective action or treatment of the inspiratory airflow limitation to modify the symptoms of functional somatic syndromes. (Specification, ¶ [0056]).

Obstructive sleep apnea and other similar disorders such as snoring, on the other hand, are commonly known to be caused by a fully or partially collapsed airway. Such sleep-disordered breathing has never been considered by those skilled in the art to be a functional somatic syndrome and is not part of any medical listing known to Appellant identifying or grouping the functional somatic syndromes. Treating patients known to experience a collapsed airway during sleep through the use of an oral device or positive airway pressure therapy is common in the Sleep Medicine field and is generally the subject of the Thornton reference. Appellant does not contest that the Thornton device is suitable for use in treating obstructive sleep apnea, snoring, and the like and may even be used in Appellant’s claimed method for treating functional somatic syndromes as the Thornton device conventionally relieves, at least partially, an obstructed airway. However, it is abundantly clear from the plain text of Thornton that the disclosed CPAP-aided oral device is not directed to, nor is there any relevant teaching or suggestion in Thornton for, the treatment of the functional somatic syndromes.

As noted previously, it is the Appellant that has first identified the likely primary role of inspiratory airflow limitation during sleep and the functional somatic syndromes and proposed and developed a treatment regime in the form of stabilizing a patient’s upper airway with positive airway pressure therapy and/or mechanical stabilization as specific examples. This discovery and methodological treatment implementation is a pioneering recognition and development in the medical field completely unrecognized by Thornton directly or through

reasonable implication or derivation of its teachings. Further evidence of this fact can be found in the Sanders Declaration. Dr. Sanders, a recognized expert in the field of Sleep Medicine, states that, “[t]he device disclosed in Thornton is intended to treat sleep disordered breathing such as snoring and sleep apnea using positive airway pressure therapy. The device is not intended to or disclosed in any way as being suitable for treating functional somatic syndromes.” (Sanders Declaration, ¶ 8).

With the foregoing in mind, upon comparing the scope and content of the single piece of applied art and the claimed invention as embodied in claim 1, it can be concluded that there are fundamentally distinct and irreconcilable differences between the subject matter of claim 1 and the applied art (Thornton). First and foremost, Thornton is utterly silent on the subject of functional somatic syndromes, failing to mention the functional somatic syndromes (expressly or by implication) or patients suffering therefrom, much less a potential causal link between inspiratory airflow limitation during sleep and these syndromes. By extension, it is clear that Thornton does not (or cannot) disclose or suggest a step of identifying a patient determined to be suffering from inspiratory airflow limitation during sleep as having a functional somatic syndrome. Moreover, Thornton completely fails to teach or suggest a step of treating a patient identified as having a functional somatic syndrome with an upper airway stabilization technique. This latter step is based on Appellant’s pioneering discovery that the functional somatic syndromes can likely be successfully treated through stabilization of a patient’s upper airway with positive airway pressure therapy and/or mechanical stabilization as specific examples. The conventional obstructive sleep apnea/snoring treatment apparatus disclosed by Thornton is limited to treating a patient suffering from sleep-disordered breathing of known causation (i.e., a fully or partially collapsed airway) with a conventional oral device optionally coupled with continuous positive airway pressure therapy.

3. The Level of Ordinary Skill in the Pertinent Art

The foregoing enumerated differences between the Thornton disclosure and the subject matter of claim 1 are confirmed by Dr. Sanders (in his Declaration), who, as a medical doctor primarily practicing in the field of Sleep Medicine, is clearly one of ordinary skill in the pertinent art. Dr. Sanders states in his Declaration that, “[t]he device disclosed in Thornton is

intended to treat sleep disordered breathing such as snoring and sleep apnea...[and] is not intended to or disclosed in any way as being suitable for treating functional somatic syndromes.” (Sanders Declaration, ¶ 8). Dr. Sanders further confirms that, “Thornton does not disclose or suggest a possible relationship between inspiratory airflow limitation during sleep and the functional somatic syndromes”. *Id.* In light of the foregoing, it is thus clear that there exist fundamentally distinct differences between the Thornton reference and the subject matter recited by Appellant in claim 1.

4. The Office Action Fails to Support the Rejection of Claim 1 Under 35 U.S.C. § 103(a) Over Thornton

In order for an invention to be properly rejected under 35 U.S.C. § 103(a), there must be an explicit rationale explaining why, despite the differences between the applied art and the claimed invention, the claimed invention would have been obvious to one of ordinary skill in the art. *KSR*, 82 U.S.P.Q.2d at 1396. Because there has been no explicit rationale offered in the Office Action that explains why Appellant’s claimed method, as embodied in claim 1, would have been obvious over Thornton despite the distinct differences present between the subject matter of claim 1 and Thornton, the rejection of claim 1 must be reversed.

As explained previously, Appellant has discovered a pioneering causal link between inspiratory airflow limitation during sleep and the functional somatic syndromes. This pioneering discovery led Appellant to develop a treatment method in which a patient determined to be suffering from inspiratory airflow limitation and identified as having a functional somatic syndrome is treated with an upper airway stabilization technique such as positive airway pressure therapy as one example. Thornton, on the other hand, is limited to the conventional treatment of obstructive sleep apnea and snoring, disorders of known causation, through the use of a conventional lower jaw repositioning oral device optionally coupled with a continuous positive airway pressure system. Despite these clear differences enumerated previously between Thornton and claim 1, the Office Action provides only a cursory and conclusionary treatment of claim 1 which appears on pages 3-4 of the Office Action. An explicit rationale explaining why, despite the differences between the applied art and the claimed invention, the claimed invention would have been obvious to one of ordinary skill in the art is entirely missing in the Office Action. *KSR*, 82 U.S.P.Q.2d at 1396.

In the Office Action, it is contended that since Thornton teaches his oral device is for treating breathing disorders, and Appellant has listed sleep apnea and snoring as disorders/diseases that are considered functional somatic syndromes, Thornton teaches a device capable of providing treatment for a functional somatic syndrome. The foregoing reasoning in the Office Action fails on at least two accounts. First, Appellant has not, in fact, listed obstructive sleep apnea and snoring as disorders or diseases that are considered functional somatic syndromes. Appellant discussed obstructive sleep apnea and snoring in connection with a method of diagnosing *sleep disorders in general*, of which obstructive sleep apnea and snoring may be a symptom. (Specification, ¶¶ [0014-0015]). This method was the subject of original claims 21-28, which are not part of this appeal.¹ Thus, the reasoning present in the Office Action in support of the rejection of claim 1 is fundamentally flawed and based on an incorrect reading of Appellant's disclosure relating to a possible method of diagnosing sleep disorders which may stem currently from Appellant's work in the field of functional somatic syndromes. This diagnostic method has been identified in the prosecution as a patentably distinct concept from the method addressed in claim 1 and was the subject matter of a Restriction Requirement issued on August 16, 2005. In response to this Restriction Requirement, Appellant elected to pursue the subject matter of independent claims 1 and 12 rather than the concept embodied in original claims 21-28. The diagnostic method in original claims 21-28 is not the subject of this Appeal and is properly the subject of a divisional application.

Second, whether or not the Thornton device is *capable* of treating a functional somatic syndrome is of no consequence to the patentability of the method claimed in claim 1. Claim 1 is directed to a method of treating functional somatic syndromes which may include a treatment device much like that disclosed by Thornton. Thornton discloses the use of an oral device optionally in conjunction with positive airway pressure therapy to treat obstructive sleep apnea and snoring. That this device is capable of being used in other, unknown methods does not render these new methods unpatentable since a new use of a known device is clearly

¹ For example, claim 21, which is representative of the non-elected claims, reads:

“21. A method of diagnosing a sleep disorder comprising the steps of:
determining whether a patient suffers from one or more symptoms of a functional somatic syndrome; and
diagnosing such a patient as having sleep-disordered breathing.”

patentable. 35 U.S.C. §§ 100-101; *see also In re King*, 801 F.2d 1324, 1327, 231 U.S.P.Q. 136, 138 (Fed.Cir. 1986) (affirming that “the discovery of a new use for an old structure based on unknown properties of the structure” could be “patentable to the discoverer as a process”). Moreover, Appellant is of the opinion that the Office Action has in fact put forward an inherency rejection but has re-couched this rejection in “obviousness” form by arguing that since the Thornton oral device is *capable* of treating a functional somatic syndrome it would inherently be obvious to do so. Such reliance on “inherency,” however, is misplaced. The issued rejection is for obviousness under 35 U.S.C. § 103(a), and obviousness cannot be predicated on something allegedly inherently present in the prior art but unknown to those skilled in the art. *In re Spormann*, 363 F.2d 444, 448, 150 U.S.P.Q. 449, 452 (CCPA, 1966) (“That which may be inherent is not necessarily known. Obviousness cannot be predicated on what is unknown.”). In any event, there is nothing “inherently” present in Thornton that would teach one skilled in the art to treat the functional somatic syndromes with an airway stabilization technique. Dr. Sanders particularly noted in this regard that “[t]he device disclosed in Thornton is intended to treat sleep disordered breathing such as snoring and sleep apnea...[and] is not intended to or disclosed in any way as being suitable for treating functional somatic syndromes.” (Sanders Declaration, ¶ 8). Dr. Sanders further confirms that, “Thornton does not disclose or suggest a possible relationship between inspiratory airflow limitation during sleep and the functional somatic syndromes.” *Id.*

Fundamentally, the Office Action makes a leap in logic that a recognized expert in the field of Sleep Medicine declares is not present in Thornton, namely, that one skilled in the art would immediately think to use the Thornton oral device to treat functional somatic syndromes. Only Appellant’s disclosure provides this explicit teaching. Furthermore, Thornton similarly cannot satisfy the requirements of an anticipation rejection under 35 U.S.C. § 102 because it fails to disclose, inherently or otherwise, anything remotely connected with the functional somatic syndromes let alone the claimed steps of determining whether inspiratory airflow during sleep is present, identifying such a patient as having a functional somatic syndrome, and treating such a patient with upper airway stabilization technique(s). Thornton contains not even a modicum of disclosure related to the functional somatic syndromes which would support an anticipation rejection.

Next, the Office Action states that since it is known in the art that “diagnosis follows treatment” (it is assumed the Office Action meant to state “treatment follows diagnosis”), a physician has to identify a patient as having a functional somatic syndrome prior to prescribing treatment with Thornton’s device. This rationale, however, fails to explain how Thornton’s disclosure would have made it obvious to identify a patient suffering from inspiratory airflow limitation during sleep as having a functional somatic syndrome. As explained previously, Thornton is in no way directed to the treatment and diagnosis of functional somatic syndromes (overtly or “inherently”). Accordingly, Thornton also fails to disclose any connection between inspiratory airflow limitation during sleep and the functional somatic syndromes. Without knowledge of this relationship, which according to Dr. Sanders is not common medical knowledge in the field of Sleep Medicine, a physician would neither diagnose a patient suffering from inspiratory airflow limitation during sleep as having a functional somatic syndrome nor treat that patient with one or more upper airway stabilization techniques.

As further support that one skilled in the art would not find the subject matter of claim 1 to have been obvious over Thornton, Appellant refers to the Sanders Declaration. In his declaration, Dr. Sanders indicates that one skilled in the art reading Thornton would not be directed to use the Thornton device for treating patients suffering from functional somatic syndromes. (Sanders Declaration, ¶ 8). Dr. Sanders further indicates that the device disclosed in Thornton is only intended to treat sleep disordered breathing such as snoring and sleep apnea using positive airway pressure and is not disclosed as being suitable for treating functional somatic syndromes. *Id.* Dr. Sanders concludes by stating that until Appellant’s recent disclosure, the use of a CPAP device to treat functional somatic syndromes was unknown and, consequently, untried and such a device would not have been used by one skilled in the art to treat a functional somatic syndrome, and it would be non-obvious to do so. *Id.*

In light of the foregoing remarks, the Office Action fails to set forth a *prima facie* case of obviousness as to claim 1. In view of the differences between the claimed subject matter and the applied art and lack of supporting rationale in the Office Action which does not explain with the requisite degree of clarity why one skilled in the art would find the method of treating

functional somatic syndromes recited in claim 1 obvious, the rejection of claim 1 should be reversed.

B. Claim 12 Was Not Properly Rejected Since the Required *Prima Facie* Case of Obviousness Under 35 U.S.C. § 103(a) Over Thornton Has Not Been Established.

Claim 12 also stands rejected under 35 U.S.C. § 103(a) for obviousness over Thornton alone. Appellant respectfully submits that the Office Action fails to establish a *prima facie* case of obviousness of claim 12 over Thornton and the rejection of this claim should also be reversed.

1. Scope and Content of the Prior Art

Because claim 12 stands rejected over Thornton as applied to claim 1, the first inquiry under the *John Deere* factors is the same as discussed *supra* in Section VII. A. 1.

2. Differences Between the Prior Art and the Claimed Invention

Claim 12 is directed to a method of treating functional somatic syndromes by: determining whether a patient suffers from inspiratory airflow limitation during sleep, identifying the patient as suffering from one or more symptoms of a functional somatic syndrome, and treating the patient with an upper airway stabilization technique. This method, like the method recited in claim 1, is based on Appellant's pioneering recognition and discovery that inspiratory airflow limitation during sleep demonstrably plays a primary role in development of the functional somatic syndromes and, as a result, treatment of inspiratory airflow limitation via an upper airway stabilization technique can be used to improve the symptoms associated with the functional somatic syndromes. Because functional somatic syndromes are disorders not usually associated with a known and identifiable physical abnormality, a patient suffering from a functional somatic syndrome or syndromes is often more easily identified by the physical symptoms he or she experiences than by any demonstrable structural change or organic disease. (Specification, ¶ [0005]). Examples of some of the symptoms most commonly associated with a functional somatic syndrome have been provided by Appellant, though one skilled in the art would understand this list to be non-exhaustive. (Specification, ¶ [0011]). Appellant's pioneering discovery of a causal linkage between restricted or limited inspiratory airflow during

sleep and the functional somatic syndromes has led to the development of the treatment method set forth in claim 12, which is slightly modified from claim 1, as this claim specifically calls out for identifying “symptom(s)” of a functional somatic syndrome rather than the full syndrome itself. Appellant’s claim 12 identifies that once inspiratory airflow limitation during sleep is determined and one or more symptoms of a functional somatic syndrome is identified, the patient can be treated with an upper airway stabilization technique, such as positive airway pressure therapy in one embodiment.

Appellant’s previous comments concerning Thornton respective to claim 1 are equally applicable to claim 12 and are incorporated herein by reference. As Thornton clearly fails to teach or suggest any potential causal connection or linkage between inspiratory airflow limitation during sleep and the functional somatic syndromes, it is readily apparent that this reference is likewise silent with respect to “symptoms” associated with the functional somatic syndromes according to claim 12. Accordingly, from the text of Thornton, it is abundantly apparent that the oral device disclosed therein is not directed to the treatment of a patient identified as having one or more symptoms of a functional somatic syndrome, which symptoms are completely unique from the symptoms associated with the disorders treated in Thornton, namely obstructive sleep apnea and snoring. Appellant’s discovery that a patient identified as suffering from one or more symptoms of a functional somatic syndrome can be treated through stabilization of the patient’s upper airway with, for example, positive airway pressure therapy is a pioneering recognition in the medical field that is completely unrecognized by Thornton directly or through reasonable implication of its teachings.

In light of the foregoing comments, upon comparing the scope and content of the single piece of applied art and the claimed invention as embodied in claim 1, it is clear that there are fundamentally distinct and irreconcilable differences between the subject matter of claim 12 and the applied art (Thornton). With respect to claim 12, as noted previously in connection with claim 1, Thornton is utterly silent on the subject of functional somatic syndromes, failing to mention the functional somatic syndromes (expressly or by implication) or patients suffering therefrom, and, moreover, is completely silent regarding any “symptoms” which could be implied to be related to one or more of the functional somatic syndromes. Thornton does not

even mention specific “symptoms” associated with obstructive sleep apnea and snoring which are ailments which the disclosed oral device is intended to treat. Without even enumerating a single such “symptom” one skilled in the art could not then even arguably extrapolate to a “symptom” of the functional somatic syndromes from the Thornton disclosure. Moreover, Thornton completely fails to teach or suggest a step of treating a patient identified as having one or more symptoms of a functional somatic syndrome with an upper airway stabilization technique. Furthermore, Thornton completely fails to teach or suggest a step of treating a patient identified as having one or more symptoms of a functional somatic syndrome with an upper airway stabilization technique since this step is based on Appellant’s pioneering discovery that the functional somatic syndromes can likely be successfully treated through stabilization of a patient’s upper airway with positive airway pressure therapy and/or mechanical stabilization as specific examples.

3. The Level of Ordinary Skill in the Pertinent Art

Appellant’s comments in Section VII. A. 3. are incorporated herein by reference.

4. The Office Action Fails to Support the Rejection of Claim 12 Under 35 U.S.C. § 103(a) Over Thornton

Because there has been no explicit rationale offered in the Office Action that explains why Appellant’s claimed method, as embodied in claim 12, would have been obvious over Thornton despite the distinct differences present between the subject matter of claim 12 and Thornton, the rejection of claim 12 must be reversed.

As explained previously in connection with claim 1, Appellant has discovered a pioneering causal link between inspiratory airflow limitation during sleep and the functional somatic syndromes. This pioneering discovery led Appellant to develop a treatment method in which a patient determined to be suffering from inspiratory airflow limitation and identified as having a functional somatic syndrome is treated with an upper airway stabilization technique such as positive airway pressure therapy as one example. Claim 12 extends this pioneering link to identifying one or more symptoms of a functional somatic syndrome rather than the syndrome itself but is otherwise similar in scope to claim 1. As with claim 1, the Office Action provides only a cursory and conclusionary treatment of claim 12 which appears on pages 5-6 of the Office

Action. An explicit rationale explaining why, despite the differences between the applied art and the claimed invention, the claimed invention would have been obvious to one of ordinary skill in the art is entirely missing in the Office Action. *KSR*, 82 U.S.P.Q.2d at 1396.

Because the rationale applied in the Office Action in rejecting claim 12 mirrors that provided in the rejection of claim 1, Appellant incorporates herein the arguments presented *supra* in Section VII. A. 4. Appellant submits that the rationale presented in the Office Action in rejecting claim 12 suffers from the same deficiencies as that offered in rejecting claim 1 since, as previously explained, Thornton similarly fails to disclose or suggest any potential link between inspiratory airflow limitation during sleep, one or more symptoms of the functional somatic syndromes, and a treatment method using upper airway stabilization. Consequently, Appellant's previous arguments are adequate to establish that the rejection of claim 12 should also be reversed and will not be repeated here.

In light of the foregoing remarks, the Office Action fails to set forth a *prima facie* case of obviousness as to claim 12. In view of the differences between the claimed subject matter and the applied art and lack of supporting rationale in the Office Action which does not explain with the requisite degree of clarity why one skilled in the art would find the method of treating functional somatic syndromes recited in claim 12 obvious, the rejection of claim 12 should be reversed.

Application No. 10/755,038
In Reply to Notice of April 7, 2008
Paper Dated: May 7, 2008
Attorney Docket No. 2111-040037


CONCLUSION

In view of the foregoing, it is respectfully submitted that the rejections of claims 1, 5, 6, 8-12, 16, 17, 19, and 20 under 35 U.S.C. § 103(a) are improper, and all of the pending claims are allowable. Appellant therefore respectfully urges the Board to reverse the Examiner's final rejections of these claims.

The Commissioner for Patents and Trademarks is hereby authorized to charge any fees which may be required to Deposit Account No. 23-0650. Please refund any overpayment to Deposit Account No. 23-0650.

Respectfully submitted,

THE WEBB LAW FIRM

By 
Kent E. Baldauf, Jr.
Registration No. 36,082
Attorney for Appellant
700 Koppers Building
436 Seventh Avenue
Pittsburgh, Pennsylvania 15219
Telephone: 412-471-8815
Facsimile: 412-471-4094
E-mail: webblaw@webblaw.com

CLAIMS APPENDIX

1. A method of treating functional somatic syndromes comprising the steps of:

determining whether a patient suffers from inspiratory airflow limitation during sleep;

identifying such a patient as having a functional somatic syndrome; and

treating such a patient with an upper airway stabilization technique;

wherein treating such a patient with an upper airway stabilization technique comprises stabilizing the airway with positive airway pressure therapy.

5. The method as claimed in claim 1, wherein the positive airway pressure therapy is selected from the group consisting of: continuous positive airway pressure, bi-level positive airway pressure, and auto-titrating positive airway pressure.

6. The method as claimed in claim 1, wherein identifying a patient as having a functional somatic syndrome includes identifying a symptom of the functional somatic syndrome, wherein the symptom is selected from the group consisting of: chronic fatigue, irritable bowel, migraine headaches, tension headaches, temporomandibular joint pain, premenstrual pain, sleep-onset insomnia, sleep maintenance insomnia, unrefreshing sleep, EEG evidence of sleep fragmentation, bruxism, muscle pain, muscle tenderness, heartburn, abdominal pain, abdominal urgency, diarrhea, depression, orthostatic syncope, alpha-delta sleep.

8. The method as claimed in claim 1, further comprising the step of categorizing a patient who has an inspiratory airflow limitation during sleep of approximately fifty-one to one-hundred percent of waking levels as an upper airway resistance syndrome (UARS) patient.

9. The method as claimed in claim 1, further comprising the step of categorizing a patient who has an inspiratory airflow limitation during sleep of approximately zero to fifty percent of waking levels as an obstructive sleep apnea/hypopnea (OSA/H) patient.

10. The method as claimed in claim 1, further comprising the step of observing alpha-delta sleep of such a patient to diagnose the functional somatic syndrome.

11. The method as claimed in claim 1, wherein the functional somatic syndrome is selected from the group consisting of: chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, migraine headaches, tension headaches, temporomandibular joint syndrome, Gulf War syndrome, premenstrual syndrome, multiple chemical sensitivity, sick building syndrome, repetition stress injury, side effects of silicone breast implants, chronic whiplash, and restless leg/periodic limb movement syndrome.

12. A method of treating functional somatic syndromes comprising the steps of:

determining whether a patient suffers from inspiratory airflow limitation during sleep;

identifying such a patient as having one or more symptoms of a functional somatic syndrome; and

treating such a patient with an upper airway stabilization technique;

wherein treating such a patient with an upper airway stabilization technique comprises stabilizing the airway with positive airway pressure therapy.

16. The method as claimed in claim 12, wherein the positive airway pressure therapy is selected from the group consisting of: continuous positive airway pressure, bi-level positive airway pressure, and auto-titrating positive airway pressure.

17. The method as claimed in claim 12, wherein the one or more symptoms symptom of the functional somatic syndrome are selected from the group consisting of: chronic fatigue, irritable bowel, a migraine headache, a tension headache, temporomandibular joint pain, premenstrual pain, sleep-onset insomnia, sleep maintenance insomnia, unrefreshing sleep, EEG

evidence of sleep fragmentation, bruxism, muscle pain, muscle tenderness, heartburn, abdominal pain, abdominal urgency, diarrhea, headaches, depression, orthostatic syncope, alpha-delta sleep.

19. The method as claimed in claim 12, further comprising the step of categorizing a patient who has an inspiratory airflow limitation of approximately fifty-one to one-hundred percent of waking levels as an upper airway resistance syndrome (UARS) patient.

20. The method as claimed in claim 12, further comprising the step of categorizing a patient who has an inspiratory airflow limitation of approximately zero to fifty percent of waking levels as an obstructive sleep apnea/hypopnea (OSA/H) patient.

Application No. 10/755,038
In Reply to Notice of April 7, 2008
Paper Dated: May 7, 2008
Attorney Docket No. 2111-040037

EVIDENCE APPENDIX

Declaration of Dr. Mark Sanders submitted May 21, 2007.	Made of record by the Examiner during prosecution as evidenced by Office Action of August 7, 2007.
Restriction Requirement issued August 16, 2005.	Issued by the Examiner and made of record August 16, 2005.
Response to August 16, 2005 Restriction Requirement dated September 15, 2005.	Made of record by the Examiner as acknowledged in the November 29, 2005 Office Action.

Application No. 10/755,038
In Reply to Notice of April 7, 2008
Paper Dated: May 7, 2008
Attorney Docket No. 2111-040037

RELATED PROCEEDINGS APPENDIX

NONE